ETF Overview: The State Street SPDR S&P Pharmaceuticals ETF (XPH), launched in 2006, provides broad exposure to the pharmaceuticals sector and aims to match the performance of the S&P Pharmaceuticals Select Industry Index with a low expense ratio of 0.35%.
Investment Strategy: Unlike traditional market cap weighted ETFs, XPH employs smart beta strategies that focus on specific fundamental characteristics to potentially enhance risk-return performance, although not all strategies guarantee superior returns.
Performance Metrics: As of late November 2025, XPH has shown a year-to-date increase of 28.24% and a 12-month gain of 20.74%, with a beta of 0.61 indicating a higher risk profile compared to the broader market.
Comparative Options: Investors may also consider other ETFs in the pharmaceuticals space, such as iShares U.S. Pharmaceuticals ETF (IHE) and VanEck Pharmaceutical ETF (PPH), which have larger asset bases and slightly different expense ratios, or opt for traditional market cap weighted ETFs for lower-risk exposure.
Wall Street analysts forecast XPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XPH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast XPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XPH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 57.020
Low
Averages
High
Current: 57.020
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
